Toku Eyes
Toku Eyes develops AI-powered retinal image analysis software that screens for diabetic eye disease, cardiovascular risk, kidney disease, and biological age. It sells via SaaS and per-scan subscriptions to optical retailers, eye care providers, hospitals, and screening programs globally.
- Company typePrivate
- Founded2019
- HeadquartersAuckland, New Zealand
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Toku Eyes does
Toku Eyes is a private medical AI company founded in 2018-2019 from the University of Auckland, New Zealand, with primary operational headquarters in San Diego (La Jolla), California. The company develops deep-learning computer vision models that analyze retinal (fundus) photographs to detect diabetic retinopathy, age-related macular degeneration, cardiovascular disease risk, chronic kidney disease risk, and biological age. Its AI models are trained on a proprietary dataset of more than 4.3 million retinal images linked to medical records—described as the largest of its kind—and analyze 23 million or more technical parameters per image. Product portfolio includes THEIA (eye disease screening), CLAiR and ORAiCLE (cardiovascular risk assessment, FDA Breakthrough Device Designation, CE and UKCA marked), BioAge (biological age/wellness assessment), and MyKidneyAI (chronic kidney disease detection in diabetic patients, launched late 2024).
The company operates a SaaS / per-scan subscription revenue model, delivering cloud-based AI analysis that returns results in approximately 10 seconds and is designed to be camera-agnostic across major fundus cameras including Topcon's NW400, NW500, and Maestro. Go-to-market combines direct sales to eye care providers with channel partnerships through National Vision Holdings (1,300+ US retail optical stores), Topcon Healthcare (OEM camera integration), EyeCheq (retail self-service kiosks), and the Aravind Eye Care System in India (20+ clinics). The company serves four primary customer segments: eye care providers, primary care and preventive health practitioners, healthcare systems running diabetic screening programs, and consumer wellness users. Strategic investors include National Vision and Topcon (Series A co-leads, April 2023, $8M USD), Icehouse Ventures (seed lead, June 2021, NZ$3.6M), and several New Zealand government grants via Callaghan Innovation.
Key risk factors include dependence on a small leadership team, no publicly disclosed revenue, pending full US FDA clearance for CLAiR (only Breakthrough Designation is currently held), and concentration risk in the National Vision retail channel as both strategic investor and major distribution partner. The company has ISO 13485 certification and operates a wholly-owned New Zealand subsidiary (Toku Eyes Limited) under Delaware-incorporated parent Toku Inc.
Toku Eyes firmographics
Firmographics- Name
- Toku Eyes
- Legal name
- Toku Eyes Limited
- Website
- https://tokueyes.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Toku Eyes develops AI-powered retinal image analysis software that screens for diabetic eye disease, cardiovascular risk, kidney disease, and biological age. It sells via SaaS and per-scan subscriptions to optical retailers, eye care providers, hospitals, and screening programs globally.
- Ownership category
- akta.pro rank
Toku Eyes industry classification
Industry- Product category
- AI Medical Diagnostics Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Computer Integrated Systems Design (7373), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)
- akta.pro secondary industries
- Comprehensive Eye Exams & Vision Care (HLAKAKAA), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Toku Eyes is headquartered
LocationHeadquarters
- HQ city
- Auckland
- HQ country
- New Zealand
- HQ region
- Oceania
Offices2 records
Markets served
Toku Eyes business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- AI Diagnostic Software (SaaS): Cloud-based AI analysis platform deployed in eye clinics, hospitals, and healthcare settings. Healthcare providers pay for access to AI diagnostic tools during routine eye exams. Revenue generated through per-scan or subscription fees integrated with existing retinal camera workflows.
- Device-as-a-Service: Medical device model providing AI software with hardware integration (special cameras). Particularly relevant for emerging markets like India where the company provides complete screening solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | BioAge wellness assessment |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
Toku Eyes product offering
Product offeringCore offering
Toku Eyes develops AI-powered software that analyzes retinal photographs to detect and assess risk for multiple health conditions including diabetic retinopathy, age-related macular degeneration, cardiovascular disease, chronic kidney disease, and biological age. The company's cloud-based diagnostic platform is delivered as software-as-a-service to eye care providers, healthcare systems, optical retailers, and primary care clinics, integrating with existing fundus cameras to deliver screening results in approximately 10 seconds.
Differentiator
Problem solved
Functional benefit
Brands
- BioAge: AI-powered biological age assessment tool using retinal photography to estimate biological age and health risk levels
- CLAiR
- MyKidneyAI
- THEIA
Products and services
- BioAge BioAge determines a person's biological age, indicating overall health, by analyzing vascular and metabolic indicators present in retinal images. It processes patient demographic data combined with retinal images to produce biological age assessments and health risk scores. Aimed at wellness consumers seeking health insights during routine eye exams, and at eye care providers offering wellness add-on services.
- MyKidneyAI MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated risk of chronic kidney disease in people with diabetes. It is intended for deployment by eye care providers, primary care clinicians, and healthcare systems managing diabetic populations. Varying regulatory status by region.
- THEIA THEIA is an AI screening platform for diabetic retinopathy, age-related macular degeneration, and other eye diseases. It analyzes retinal images using deep learning to detect referable eye disease with 100% sensitivity and 95.35%-97.44% specificity in multi-center prospective trials. The platform is camera-agnostic, handles lower-quality images, and works with any number of images per eye. Deployed in optometry practices, ophthalmology clinics, and eye hospitals globally.
- CLAiR CLAiR is an AI-powered cardiovascular disease risk assessment tool that analyzes retinal images to provide immediate, non-invasive assessment of ASCVD risk comparable to gold-standard cardiovascular risk calculations. The tool recognizes minute changes in blood vessels and capillaries to determine risk of cardiovascular events and is claimed to be 25% more accurate than AHA and Mayo Clinic risk assessment tools. Aimed at primary care physicians, cardiologists, preventive health providers, optical retailers, and pharmacy screening programs.
Quantifiable outcome
- 100% sensitivity for diabetic retinopathy detection in multi-center trial (902 patients)
- +4 more outcomes
Companies that use Toku Eyes
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Toku Eyes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Toku Eyes partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core, secondary and infrastructure.
- American Heart Association Center for Health Technology & InnovationflagshipToku joined AHA's Innovators' Network - a healthcare technology consortium connecting entrepreneurs, providers, researchers, and payers. Access to AHA's digital guidelines, recommendations, and best-in-class science. Collaboration on evidence-based health tech solutions and clinical outcome studies.
- EyeCheqcoreCompany building self-service retinal image kiosks in retail locations across the US. Integrating Toku's AI software to provide automated cardiovascular risk assessment at kiosks without requiring clinician review of all images.
- Unified-ImagingsecondaryCloud-based image repository platform gathering images from camera manufacturers. Toku works with Unified-Imaging to provide data analytics platform for cardiovascular and kidney risk detection from retinal images.
- Aravind Eye Care System (India)coreLargest eye hospital chain in the world, seeing 4 million patients annually and performing 500,000 eye surgeries. THEIA deployed in 20+ eye clinics in India for diabetic retinopathy screening.
- Amazon Web Services (AWS)infrastructureAWS listed as technology partner/investor. Cloud infrastructure provider for Toku's AI platform processing retinal images.
- NVIDIAinfrastructureNVIDIA listed as partner. Likely provides GPU computing infrastructure for AI model training and inference on retinal image analysis.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
Toku Eyes competitors and assessment
Company assessmentDirect peers
- Eyenuk: Eyenuk's EyeArt is the most widely deployed FDA-cleared AI system for autonomous diabetic retinopathy screening — the same core use case as Toku's THEIA. Both target optometry/ophthalmology channels with camera-agnostic AI on fundus images, making them direct competitors for screening program contracts.
- Digital Diagnostics (IDx-DR): Digital Diagnostics' IDx-DR was the first FDA-authorized autonomous AI diagnostic and pioneered retail-clinic deployment (e.g., with retail pharmacy partners). It directly competes with Toku on AI-driven diabetic retinopathy screening at the point of care, including non-traditional settings like primary care.
- AEYE Health: AEYE Health provides FDA-cleared AI for diabetic retinopathy screening from retinal images, competing head-to-head with THEIA. Like Toku, it pursues retail, primary care, and optometry channels and emphasizes a single-image, camera-agnostic workflow.
Emerging players
- HeartFlow: HeartFlow applies AI to a different cardiovascular imaging modality (CT angiography) for non-invasive assessment of coronary artery disease. It is comparable to CLAiR's mission of replacing invasive/expensive CVD workups with AI imaging analysis, but in a different anatomical window than the retina.
- Cleerly: Cleerly uses AI on cardiac CT to characterize plaque and stratify cardiovascular risk, pursuing a similar preventive-CVD thesis to CLAiR. Comparable as a venture-stage AI cardiovascular diagnostics company chasing non-invasive, imaging-based risk assessment.
- iHealthScreen: iHealthScreen offers AI-based retinal screening for diabetic retinopathy and age-related macular degeneration, with FDA clearance. It is comparable to Toku THEIA in scope (eye disease detection) and target customer (primary care, optometry, retail clinics).
Broad incumbents
- Aidoc: Aidoc is a broader AI medical imaging platform deployed across hospital radiology workflows. While not focused on retinal imaging, it is a comparable AI-imaging-diagnostics company pursuing similar health-system contracts and regulatory pathways, and represents potential adjacent competition for clinical AI budgets.
- Google Health (retinal AI research): Google published landmark research on using retinal images to predict cardiovascular risk — directly comparable to CLAiR's premise. As a well-capitalized tech incumbent with global reach, Google represents a strategic threat if it commercializes retinal CVD screening, and a potential acquirer.
Others
- Topcon Healthcare: Topcon is Toku's Series A co-lead, camera partner, and reseller for the NW400/NW500/Maestro fundus cameras. It is both a critical channel and a potential competitor if Topcon bundles or develops its own AI screening — making its strategic posture pivotal to Toku's trajectory.
- Optos (Nikon): Optos is a leading ultra-widefield retinal imaging manufacturer and a Toku integration partner via the Unified-Imaging cloud repository. As a camera ecosystem gatekeeper, Optos shapes Toku's access to the installed base and is a potential competitor or partner depending on its AI strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Toku Eyes social profiles
Digital presenceToku Eyes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Toku Eyes leadership team
Management profileNumber of profiles
Profiles14 records
Toku Eyes subsidiaries and ownership
Company hierarchySubsidiaries1 record
Toku Eyes funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Toku Eyes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Toku Eyes
What does Toku Eyes do?
Toku Eyes develops AI-powered software that analyzes retinal photographs to detect and assess risk for multiple health conditions including diabetic retinopathy, age-related macular degeneration, cardiovascular disease, chronic kidney disease, and biological age. The company's cloud-based diagnostic platform is delivered as software-as-a-service to eye care providers, healthcare systems, optical retailers, and primary care clinics, integrating with existing fundus cameras to deliver screening results in approximately 10 seconds.
Is Toku Eyes a public or private company?
Toku Eyes is a private company. It is classified as venture growth investor backed and is currently operating.
When was Toku Eyes founded?
Toku Eyes was founded in 2019. It employs 11 to 50 people.
Where is Toku Eyes based?
Toku Eyes is headquartered in Auckland, New Zealand, in the Oceania region.
How does Toku Eyes make money?
Two revenue lines are on record. AI Diagnostic Software (SaaS) is the primary driver. The others are device-as-a-Service.
Who are Toku Eyes's main competitors?
Direct peers on record are Eyenuk, Digital Diagnostics (IDx-DR) and AEYE Health. Emerging players are HeartFlow, Cleerly and iHealthScreen. Broad incumbents are Aidoc and Google Health (retinal AI research). Others are Topcon Healthcare and Optos (Nikon).
Does Toku Eyes have an API?
No public API is recorded for Toku Eyes.
What industry is Toku Eyes in?
Toku Eyes's product category is AI Medical Diagnostics Software. Its primary akta.pro industry code is HLALAGAL, Ophthalmology & Vision Telemedicine Platforms, with a secondary code of HLAKAKAA, Comprehensive Eye Exams & Vision Care. Its NAICS code is 54151 and its SIC code is 7373.